Engineering a Microfluidic Chip to Observe Alzheimer's Protein Spread: Linking Biomedical Engineering to Neuroscience Alzheimer's disease progression involves prion-like propagation of misfolded amyloid-β and tau proteins through neural circuits via trans-synaptic transfer along axonal projections. Traditional animal models and 2D cell cultures fail to recapitulate human-relevant pathophysiology and directional protein transport. Microfluidic brain-on-a-chip platforms address these limitations through compartmentalized architectures featuring source and receiver neuronal chambers connected by microgrooves (3-10 μm wide, 450 μm long) that permit axonal extension while restricting somal passage. Integrated blood-brain barrier modules enable physiologically relevant drug perfusion studies. Using human iPSC-derived neurons, astrocytes, microglia, and endothelial cells with fluorescent biosensors (FRET/FLIM), these platforms enable real-time visualization of protein spreading mechanisms, high-throughput therapeutic screening, and patient-specific disease modeling. Despite challenges including material drug absorption and device variability, advances in thermoplastic materials, AI-driven analytics, and standardized formats promise translation from bench-top research tools to FDA-approved clinical platforms for Alzheimer's diagnosis and treatment development.
Wan Kiu Winkey CHENG (Fri,) studied this question.